Skip to content

A brief history of ResBiotic

Academic Origin Story

Founder C Vivek Lal MD FAAP, together with colleagues in the Pulmonary Microbiome Lab, Microbiome Center, Lung Health Center, and Translational Research in Normal & Disordered Development (TReNDD) program at University of Alabama at Birmingham has been studying the microbiome as it relates to lung health for over a decade.

Formulating the world's first ResBiotic

Over the last few years, Dr. Lal and team developed and tested proprietary probiotic strains to support lung health. The strains have been tested independently, as a blend, and in combination with bioactive botanicals to develop an optimal formulation that supports lung structure and function*. Dr. Lal founded ResBiotic in 2020 to make his innovation accessible to the public.

Introducing resB® Lung Support

In October 2021, the company announced its first product, resB® Lung Support: a science-back probiotic supplement for lung health. At this time, the company also announced the spin out of pharmaceutical subsidiary Alveolus Bio. While ResBiotic remains focused on consumer health products, Alveolus Bio will pursue the development of breakthrough therapies for chronic lung disease.

Microbiome & The Lungs

From the moment we take our first breath, the world around us is influencing our microbiome. The microbiome is a community of commensal, symbiotic, and pathogenic organisms that share our body space. In fact, there are more bacterial cells than human cells in a healthy human body.

Research in the field initially focused on the gut microbiome and digestive health but quickly expanded to studying other organs such as the skin brain and even lungs. In recent decades scientists discovered that complex communities of microbiota inhabit the lungs and help maintain homeostasis in immune response, microbial biosis, and lung health.*

Our Scientists

Dr. C Vivek Lal MD FAAP

CEO, Founder & CSO

Associate Professor & Director Pulmonary Microbiome Lab, University of Alabama at Birmingham

Dr. Amit Gaggar MD PhD

Chief Medical Officer

Endowed Professor, Pulmonary & Critical Care Medicine & Director, Program in Matrix Biology, University of Alabama at Birmingham

Dr. Teodora Nicola MD PhD MBA

Lead Scientist

Formerly NIH Funded Scientist at University of Alabama Birmingham

Dr. Mike Wells MD

Scientific Advisor
(Clinical Trials, Adult Lung Disease)

Associate Professor, Pulmonary & Critical Care Medicine, University of Alabama at Birmingham

Dr. Yvonne Huang MD

Scientific Advisor
(Microbiome, Adult Lung Disease)

Associate Professor, Pulmonary & Critical Care Medicine & Director Huang Microbiome Lab, University of Michigan

Dr. Namasivayam Ambalavanan MD

Scientific Advisor
(Pediatric Lung Disease)

Endowed Professor & Virginia Walker Chair in Pediatrics, University of Alabama at Birmingham

Dr. Casey Morrow PhD

Scientific Advisor

Professor Emeritus, Microbiome Resource Center & Cell Development & Integrative Biology, University of Alabama at Birmingham

Dr. Kent Willis MD

Scientific Advisor
(Gut-Lung Axis, Mycobiome)

Assistant Professor & Director, Willis Lung Lab, University of Alabama at Birmingham

Dr. Nirmal Sharma MD

Scientific Advisor
(Lung Transplant)

Assistant Professor Medical Director Lung Transplantation Program, Brigham & Women’s, Harvard University

Our Process

1 - Strain Development

Our strain bank is maintained with ResBiotic’s own proprietary deposits, all backed by clinical (in vivo) and laboratory (in vitro) proof of concept and safety data. Our blend is formulated by optimizing indicative biomarker responses in tissue cells to better optimize support for the lungs. All of our strains have had their full genomes sequenced.

2 - Botanical Formulation

Each capsule contains ancient botanical extracts produced in a cGMP (Current Good Manufacturing Processes) environment by FDA-certified suppliers, specifically processed for extended stability and probiotic longevity. The combination of probiotics and botanical extracts combine to create a truly unique formulation, tailored toward lung support.

3- Production

ResBiotic’s strain blend is produced via biofermentation at massive scale through optimizing fermentation temperature, pH, mother culture purity, and other factors. Each strain is enumerated and precision-blended to yield a consistent colony forming unit (CFU) count in each capsule, every time.

4 - Blend

Our science-derived dosage has been created based on nearly a decade of research into representative and mechanistic gut and lung models, both in vitro and in vivo. Because we value product integrity, we recommend you refrigerate our products to maintain maximum bacteria cell count and effectiveness. Important foods require extra care.

5 - Quality

Every batch of bacteria is cultured, concentrated, lyophilized (freeze-dried), jet-milled, analyzed for impurities, and precision-blended according to current Good Manufacturing Practices (cGMP) from FDA-compliant manufacturing facilities, and sent to you from our FDA-registered fulfillment center. We only release to the public products that have met stringent quality, purity, and analytical testing requirements.

6 - Safety

Our strains are recognized by the FDA as GRAS (Generally Recognized as Safe). Our products (and every ingredient in our products) has been clinically tested in humans and shown to be safe. Your safety and your lung health are our priority - in that order.